Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080987 | 0.88 | ALDH1A1 (0.43) | ALDH1A1TSHRHRH3CTSLCTSS | |
| SCHEMBL6081705 | 0.83 | HRH3 (0.39) | ALDH1A1TSHRHRH3CTSLCTSS | |
| SCHEMBL6081381 | 0.81 | HRH3 (0.38) | ALDH1A1TSHRHRH3ACACBACACA | |
| SCHEMBL6082261 | 0.80 | CYP19A1 (0.42) | ALDH1A1TSHRKDM4E | |
| SCHEMBL1728613 | 0.75 | HRH3 (0.46) | ALDH1A1TSHRHRH3ACACB | |
| SCHEMBL6081179 | 0.73 | HRH3 (0.41) | ALDH1A1HRH3KDM4EACACB | |
| SCHEMBL6081508 | 0.72 | KDM4E (0.50) | ALDH1A1TSHRHRH3KDM4E | |
| SCHEMBL1728644 | 0.72 | HRH3 (0.42) | ALDH1A1TSHRHRH3KDM4EACACB | |
| SCHEMBL6081904 | 0.72 | HRH3 (0.42) | ALDH1A1TSHRHRH3KDM4EACACB | |
| SCHEMBL1727601 | 0.71 | KDM4E (0.52) | ALDH1A1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141561-B2 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | GPR119, GLP1R, SLC5A2 | ALDH1A1 1096/4885TSHR 919/4885HRH3 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.